Open AccessCost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With EGFR Mutations In China
Author(s) -
Bairong Shen,
Li Chen,
J.J. Meana
Publication year - 2021
Publication title -
proceedings of mol2net'21, conference on molecular, biomedical and computational sciences and engineering, 7th ed.
Language(s) - English
Resource type - Conference proceedings
DOI - 10.3390/mol2net-07-11615
Subject(s) - gefitinib , medicine , lung cancer , oncology , epidermal growth factor receptor , chemotherapy , cost effectiveness , cost effectiveness analysis , quality adjusted life year , cancer , risk analysis (engineering)